T

Transgene

209 employees

Cancer immunotherapy Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing novel immunotherapies for the treatment of cancer.

Investor insights

Funding rounds participated in

$16M sweet spot round size

Investor type

Public Company

Basic info

Industry

Biotechnology

Sectors

Biotechnology

Date founded

1979

Funding rounds raised

Total raised

$16M

from investors over 1 rounds

T

Transgene raised $16M on August 17, 2023